These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
200 related articles for article (PubMed ID: 32627277)
21. Intravenous immunoglobulin for chronic inflammatory demyelinating polyradiculoneuropathy: the ICE trial. Hughes RA Expert Rev Neurother; 2009 Jun; 9(6):789-95. PubMed ID: 19496683 [TBL] [Abstract][Full Text] [Related]
22. Immunoglobulin administration for the treatment of CIDP: IVIG or SCIG? Allen JA; Gelinas DF; Freimer M; Runken MC; Wolfe GI J Neurol Sci; 2020 Jan; 408():116497. PubMed ID: 31765922 [TBL] [Abstract][Full Text] [Related]
23. A randomised, multi-centre phase III study of 3 different doses of intravenous immunoglobulin 10% in patients with chronic inflammatory demyelinating polyradiculoneuropathy (ProCID trial): Study design and protocol. Cornblath DR; Hartung HP; Katzberg HD; Merkies ISJ; van Doorn PA J Peripher Nerv Syst; 2018 Jun; 23(2):108-114. PubMed ID: 29603842 [TBL] [Abstract][Full Text] [Related]
24. Long-term neurophysiological and clinical response in patients with chronic inflammatory demyelinating polyradiculoneuropathy treated with subcutaneous immunoglobulin. Cirillo G; Todisco V; Tedeschi G Clin Neurophysiol; 2018 May; 129(5):967-973. PubMed ID: 29554579 [TBL] [Abstract][Full Text] [Related]
25. Manual push technique, an alternative route of subcutaneous immunoglobulin administration in chronic inflammatory demyelinating polyradiculoneuropathy: A proof-of-concept study. Cocito D; Peci E; Rigaldo S; Canavese C; Migliaretti G; Cossa FM Clin Neurol Neurosurg; 2020 Nov; 198():106240. PubMed ID: 32971302 [TBL] [Abstract][Full Text] [Related]
27. Assessing deterioration using impairment and functional outcome measures in chronic inflammatory demyelinating polyneuropathy: A post-hoc analysis of the immunoglobulin overtreatment in CIDP trial. van Veen R; Wieske L; Lucke I; Adrichem ME; Merkies ISJ; van Schaik IN; Eftimov F J Peripher Nerv Syst; 2022 Jun; 27(2):144-158. PubMed ID: 35507446 [TBL] [Abstract][Full Text] [Related]
28. Subcutaneous immunoglobulin in responders to intravenous therapy with chronic inflammatory demyelinating polyradiculoneuropathy. Markvardsen LH; Debost JC; Harbo T; Sindrup SH; Andersen H; Christiansen I; Otto M; Olsen NK; Lassen LL; Jakobsen J; Eur J Neurol; 2013 May; 20(5):836-42. PubMed ID: 23294032 [TBL] [Abstract][Full Text] [Related]
29. Protocol of a dose response trial of IV immunoglobulin in chronic inflammatory demyelinating polyradiculoneuropathy (DRIP study). Kuitwaard K; Fokkink WR; Brusse E; Vrancken AFJE; Eftimov F; Notermans NC; van der Kooi AJ; Merkies ISJ; Jacobs BC; van Doorn PA J Peripher Nerv Syst; 2018 Mar; 23(1):5-10. PubMed ID: 29119642 [TBL] [Abstract][Full Text] [Related]
30. Long-term treatment with subcutaneous immunoglobulin in patients with chronic inflammatory demyelinating polyradiculoneuropathy: a follow-up period up to 7 years. Gentile L; Mazzeo A; Russo M; Arimatea I; Vita G; Toscano A Sci Rep; 2020 May; 10(1):7910. PubMed ID: 32404895 [TBL] [Abstract][Full Text] [Related]
31. Chronic Inflammatory Demyelinating Polyneuropathy: Time to Maximal Recovery in Patients Receiving Intravenous Immunoglobulin Therapy. Opala AR; Kennedy K; Baker SK Can J Neurol Sci; 2020 Jul; 47(4):531-537. PubMed ID: 32279669 [TBL] [Abstract][Full Text] [Related]
35. Subcutaneous immunoglobulin treatment in CIDP and MMN. Efficacy, treatment satisfaction and costs. Markvardsen LH; Harbo T J Neurol Sci; 2017 Jul; 378():19-25. PubMed ID: 28566163 [TBL] [Abstract][Full Text] [Related]
36. Clinical trials in CIDP and chronic autoimmune demyelinating polyneuropathies. Dalakas MC J Peripher Nerv Syst; 2012 May; 17 Suppl 2():34-9. PubMed ID: 22548621 [TBL] [Abstract][Full Text] [Related]
37. Intravenous immunoglobulin for chronic inflammatory demyelinating polyradiculoneuropathy. Van Schaik IN; Winer JB; De Haan R; Vermeulen M Cochrane Database Syst Rev; 2002; (2):CD001797. PubMed ID: 12076423 [TBL] [Abstract][Full Text] [Related]
38. A Budget Impact Model of Maintenance Treatment of Chronic Inflammatory Demyelinating Polyneuropathy with IgPro20 (Hizentra) Relative to Intravenous Immunoglobulin in the United States. Mallick R; Carlton R; Van Stiphout J Pharmacoecon Open; 2023 Mar; 7(2):243-255. PubMed ID: 36757567 [TBL] [Abstract][Full Text] [Related]
39. Intravenous immune globulin (10% caprylate-chromatography purified) for the treatment of chronic inflammatory demyelinating polyradiculoneuropathy (ICE study): a randomised placebo-controlled trial. Hughes RA; Donofrio P; Bril V; Dalakas MC; Deng C; Hanna K; Hartung HP; Latov N; Merkies IS; van Doorn PA; Lancet Neurol; 2008 Feb; 7(2):136-44. PubMed ID: 18178525 [TBL] [Abstract][Full Text] [Related]
40. Maintenance IV immunoglobulin treatment in chronic inflammatory demyelinating polyradiculoneuropathy. Kuitwaard K; Fokkink WR; Brusse E; Vrancken AFJE; Eftimov F; Notermans NC; van der Kooi AJ; Merkies ISJ; Jacobs BC; van Doorn PA J Peripher Nerv Syst; 2017 Dec; 22(4):425-432. PubMed ID: 29092099 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]